Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1998 Mar 15;18(6):2009–2016. doi: 10.1523/JNEUROSCI.18-06-02009.1998

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 1998 Society for Neuroscience

PMC Copyright notice

Fig. 6. — Effect of the monoamine uptake inhibitor imipramine on IPSCs evoked by minimal stimulation. A, Superimposed IPSCs in control (trace 1), in the presence of imipramine (1 μm; trace 2), and in the combined presence of imipramine (1 μm) and SCH23390 (0.1 μm; trace 3). Each trace represents the average of 10–15 traces. B, Time course of change in the IPSC amplitude during perfusion with imipramine (IMI) and imipramine together with SCH23390 (IMI+SCH). The amplitude of evoked IPSCs was increased by imipramine associated with a decrease in failure number. Subsequent application of SCH23390 decreased the amplitude of the IPSCs below control level, whereas the failure rate increased, indicating a tonic effect of endogenous DA on GABA release. Each point represents the amplitude of an IPSC evoked by minimal stimulation at a repetition rate of 0.1 Hz.